The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Mechanism of action of mitapivat and its potential in the treatment of SCD
Myrthe van Dijk, MD, UMC Utrecht, Utrecht, The Netherlands, explains the mechanism of action of mitapivat, an allosteric activator of pyruvate kinase with potential therapeutic efficacy in sickle cell disease (SCD). Activation of pyruvate kinase enhances metabolic processes within red blood cells to prevent their deoxygenation and the polymerization of hemoglobin S (HbS) molecules. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Axcella Health Inc., Agios Pharmaceuticals Inc.
